Chemnitz Family Diagnosed With Niemann-Pick Type C

In Chemnitz, Germany, a family’s multi-year medical odyssey revealed that their eldest daughter, Natalie, and subsequently her younger brother, David, suffer from Niemann-Pick type C—a rare, incurable neurodegenerative metabolic disorder commonly known as childhood dementia, FOCUS online reported.

In Plain English: The Clinical Takeaway

Symptom management: While treatments such as Miglustat and Arimoclomol aim to slow the progression, there is no therapy for the disease.

Uncovering a Rare Metabolic Disorder Behind Childhood Symptoms

Natalie’s symptoms began quietly around age four with balance issues, difficulty standing on one leg, and trouble interacting normally with peers. Initially dismissed by a neuropadiatrician, her condition worsened. By the time she entered school in the autumn of 2024, she struggled to keep pace with the curriculum, leading to a formal assessment of intellectual disability.

By May 2025, Natalie began suffering from sudden, uncontrolled laughter and cataplectic attacks—episodes involving a sudden loss of muscle tone that caused her to collapse. Her father, André Glöckner, initially thought she was simply fooling around. Following a family holiday in Austria, clinicians at a clinic in Brandenburg contacted the family in October 2025 with test results confirming Niemann-Pick type C. The rare condition affects only about 200 individuals in Germany, and patients rarely live past the age of 30.

Extending Testing to the Younger Sibling

Faced with the diagnosis, Glöckner connected with a support group at the University Hospital of Münster and sought guidance from specialists at the SphinCS private research center for lysosomal storage diseases in Hochheim, near Frankfurt am Main. Given that the condition is an autosomal-recessive genetic trait, the family had their younger son, David, tested as well.

Although statistical probability placed the risk at 6.25 percent, David tested positive on November 20, 2025. Before the diagnosis, David had exhibited only minor motor difficulties and slightly slurred speech. Without genetic testing, his condition would have remained undetected for years as the mutation, which both children have, typically manifests with symptoms between the ages of five and ten.

Pharmacological Interventions and Ongoing Decline

Glöckner secured treatments including Miglustat and Arimoclomol, as well as an additional medication sourced from France to address dizziness.

Now eight years old, Natalie experiences renewed cognitive fatigue, behavioral challenges, and breakthrough cataplexy, requiring another school transition. Meanwhile, six-year-old David attends a school for children with motor skill development needs and continues to make progress.

Contraindications & When to Consult a Doctor

References

FOCUS online – Investigative coverage of the Glöckner family case, published October 2026.

Keep reading